Tan Yongjun / Associate Professor

Professor, Doctoral Supervisor, Dean of the School of Biology, Hunan University

Professor, Doctoral Supervisor, Dean of the School of Biology, Hunan University, Hunan "Furong Scholar" Distinguished Professor, winner of the "New Century Excellent Talent Support Program" of the Ministry of Education, and winner of the Hunan Natural Science Outstanding Youth Fund. In 1989, he graduated from the Department of Biology, Nankai University with a bachelor’s degree in biochemistry. In 1992, he graduated with a master’s degree in molecular biology from Nankai University’s Institute of Molecular Biology. He received a PhD in Pharmacology and Molecular Biology from Chicago Medical College in 1999. From 1999 to 2006, the United States Postdoctoral, lecturer and research assistant professor in the Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago. In 2006, he served as the chief scientist of "Cell and Tissue Engineering" in the 985 Project of Hunan University. In 2008, he served as the director of the national "Biomedicine and Life Analytical Chemistry Demonstration International Science and Technology Cooperation Base". In 2010, he won the Contribution Award for Innovative Talents in the Overseas Chinese Community of China. In 2015, he served as the Dean of the School of Biology, Hunan University. Presided over the National Natural Science Foundation of China's Sino-Hong Kong cooperative research NSFC-RGC project, major international cooperation projects of the Ministry of Science and Technology, and a number of general projects of the National Natural Science Foundation of China. He has long been engaged in the research on the regulation mechanism of gene expression of tumors and stem cells, and many academic papers have been published in international professional journals. In the field of anti-cancer drug development, develop key tumor gene therapy technologies for specific genes, and establish a Chinese-style production platform for tumor gene therapy products. Develop a number of anti-cancer targeted protein peptides, carry out research on the mechanism of action, efficacy, and druggability, and obtain candidate original drugs with independent intellectual property rights.